BioGaia signs exclusive agreement in Egypt
BioGaia has signed an agreement with Minapharm Pharmaceuticals for the exclusive rights to sell BioGaia Protectis drops in Egypt. The probiotic will be sold under the BioGaia brand. Launch is planned to Q4 2021.
Minapharm is a leading pharmaceutical company in Egypt and the Middle East and the premier biopharmaceutical company in the region. Minapharm develops, manufactures and commercialises medicines ranging from small molecules to complex genetically engineered proteins, as well as develops and licenses advanced technologies in the field of proteins and also cell and gene therapy to global pharma players. Headquartered in Cairo, the company commercialises over 100 products. With a workforce of over 1,400 employees, Minapharm has established an integrated business model composed of international and regional subsidiaries.
“This agreement coincides with Minapharm’s expansion programme towards nutritional supplements. BioGaia is a world leader in probiotics and hence, a perfect fit to our broad gastroenterology portfolio in a high demand region,” says Dr. Wafik Bardissi, Chairman and CEO of Minapharm Pharmaceuticals.
“I am very happy to be able to extend our coverage in Africa by entering Egypt with a regional and professional partner,” says Isabelle Ducellier, CEO of BioGaia.
Latest press releases from BioGaia
07.04.2021 Notice to attend the Annual General Meeting of BioGaia AB (publ)
31.03.2021 BioGaia publishes annual report for 2020
17.03.2021 BioGaia Invest (BGI) – a new subsidiary focusing on innovative investments to support the growth of BioGaia